RecruitingPhase 3NCT06578247

Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML

Studying Acute promyelocytic leukemia

Last synced from ClinicalTrials.gov May 3, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Daiichi Sankyo
Principal Investigator: Global Clinical Leader
Daiichi Sankyo
Intervention: Quizartinib(drug)
Enrollment: 700 enrolled
Eligibility: 18-70 years · All sexes
Timeline: 2024 – 2030

Study locations (30)

City of Hope Phoenix, Goodyear, Arizona, United States
Mayo Clinic - Phoenix, Phoenix, Arizona, United States
University of Arizona Cancer Center, Tucson, Arizona, United States
David Geffen School of Medicine, Los Angeles, California, United States
University of California Davis Health System, Sacramento, California, United States
Ucsf - School of Medicine, San Francisco, California, United States
Stanford University School of Medicine- Parent, Stanford, California, United States
Colorado Blood Cancer Institute, Denver, Colorado, United States
Yale University, New Haven, Connecticut, United States
Mayo Clinic Hospital, Jacksonville, Florida, United States
Florida Hospital Cancer Institute - Kissimmee, Kissimmee, Florida, United States
Tampa General Hospital, Tampa, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
Augusta University, Augusta, Georgia, United States
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06578247 on ClinicalTrials.gov

Other trials for Acute promyelocytic leukemia

Additional recruiting or active studies for the same condition.

See all trials for Acute promyelocytic leukemia →

← Back to all trials